First Ascent Biomedical ^Company

First Ascent Biomedical is an organization that focuses on personalized cancer therapy using machine learning and artificial intelligence. Their main goal is to design personalized combination cancer therapy plans for individual cancer patients. They have developed a breakthrough drug prediction platform called DxPP, which utilizes AI and therapy resistant cell technologies to improve treatment planning and drug development for cancer patients. This platform has been validated and published in studies with leading cancer centers, and oncologists can benefit from its technology with an average 10-day turnaround. First Ascent Biomedical has also demonstrated the effectiveness of their Drug Prediction Platform with leading industry partners.